|
Ortiz-Fernandez P, Iniesta-Navalon C, Urbieta-Sanz E, Gascon-Canovas JJ. Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases. Clin Rheumatol. 2025 Aug;44(8):3389-3390. doi: 10.1007/s10067-025-07559-w. Epub 2025 Jul 4. No abstract available. PubMed PMID: 40613968.
AÑO: 2025; IF: 2.8
|
40613968
|
Iniesta-Navalon C, Rios-Saorin M, Anez-Castano R, Rentero-Redondo L, Ortiz-Fernandez P, Marin-Armero Martinez E, Urbieta-Sanz E. Evaluating the Accuracy and Clinical Utility of AFIAS-10 Point of Care Versus Enzyme-Linked Immunosorbent Assay in Therapeutic Drug Monitoring of Infliximab and Adalimumab. Ther Drug Monit. 2025 Jun 1;47(3):346-352. doi: 10.1097/FTD.0000000000001269. Epub 2024 Nov 15. PubMed PMID: 40341590.
AÑO: 2025; IF: 2.4
|
|
Díaz L.S., Navalón C.I., Espín R.G., de Prado I.N., Morell E.B., Redondo L.R. Impact of proactive therapeutic drug monitoring of infliximab during the induction phase in IBD patients. A Bayesian approach. Revista Espanola de Enfermedades Digestivas. 2023. 115:435-443. 10.17235/reed.2022.8781/2022
AÑO: 2023; IF: 2.7
|
|
Diaz LS, Navalon CI, Espin RG, Prado IN, Redondo LR. Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease. Gastroenterol Hepatol. 2023 Aug-Sep;46(7):504-511. doi: 10.1016/j.gastrohep.2022.10.019. Epub 2022 Nov 15. English, Spanish. PubMed PMID: 36400260.
AÑO: 2023; IF: 2.2
|
|
Iniesta Navalon C, Gil Candel M, Salar Valverde I, Nicolas de Prado I, Gomez Espin R, Rentero Redondo L. Biosimilar infliximab CPT-13 for inflammatory bowel disease in a real clinical setting: pharmacokinetic outcomes, immunogenicity, and drug survival. Rev Esp Enferm Dig. 2021 Nov;113(11):770-775. doi: 10.17235/reed.2021.7638/2020. PubMed PMID: 33486961.
AÑO: 2021; IF: 2.389
|